These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9389381)

  • 1. Inhibition of human lymphocyte proliferation by nitric oxide-releasing oxatriazole derivatives.
    Kosonen O; Kankaanranta H; Vuorinen P; Moilanen E
    Eur J Pharmacol; 1997 Oct; 337(1):55-61. PubMed ID: 9389381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide-releasing oxatriazole derivatives inhibit human lymphocyte proliferation by a cyclic GMP-independent mechanism.
    Kosonen O; Kankaanranta H; Lähde M; Vuorinen P; Ylitalo P; Moilanen E
    J Pharmacol Exp Ther; 1998 Jul; 286(1):215-20. PubMed ID: 9655862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effects of mesoionic 3-aryl substituted oxatriazole-5-imine derivatives on vascular smooth muscle cell mitogenesis and proliferation in vitro.
    Lähteenmäki T; Sievi E; Vapaatalo H
    Br J Pharmacol; 1998 Sep; 125(2):402-8. PubMed ID: 9786515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitric oxide-donating properties of mesoionic 3-aryl substituted oxatriazole-5-imine derivatives.
    Kankaanranta H; Rydell E; Petersson AS; Holm P; Moilanen E; Corell T; Karup G; Vuorinen P; Pedersen SB; Wennmalm A; Metsä-Ketelä T
    Br J Pharmacol; 1996 Feb; 117(3):401-406. PubMed ID: 8821526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical releasing properties of nitric oxide donors GEA 3162, SIN-1 and S-nitroso-N-acetylpenicillamine.
    Holm P; Kankaanranta H; Metsä-Ketelä T; Moilanen E
    Eur J Pharmacol; 1998 Apr; 346(1):97-102. PubMed ID: 9617758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition by nitric oxide-releasing compounds of prostacyclin production in human endothelial cells.
    Kosonen O; Kankaanranta H; Malo-Ranta U; Ristimäki A; Moilanen E
    Br J Pharmacol; 1998 Sep; 125(2):247-54. PubMed ID: 9786495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition by nitric oxide-donors of human polymorphonuclear leucocyte functions.
    Moilanen E; Vuorinen P; Kankaanranta H; Metsä-Ketelä T; Vapaatalo H
    Br J Pharmacol; 1993 Jul; 109(3):852-8. PubMed ID: 8395300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of relaxations of bovine isolated bronchioles by the nitric oxide donor, GEA 3175.
    Hernández M; Elmedal B; Mulvany MJ; Simonsen U
    Br J Pharmacol; 1998 Mar; 123(5):895-905. PubMed ID: 9535018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosine 5'-diphosphate-induced platelet aggregation in uremia shows resistance to inhibition by the novel nitric oxide donor GEA 3175 but not by S-nitroso-N-acetylpenicillamine.
    Whiss PA; Larsson R
    Haemostasis; 1998; 28(5):260-7. PubMed ID: 10420076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALB/C 3T3 fibroblasts by a cyclic GMP-independent mechanism.
    Garg UC; Hassid A
    Biochem Biophys Res Commun; 1990 Aug; 171(1):474-9. PubMed ID: 1697465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide inhibits cell growth in cultured human thyrocytes.
    Motohashi S; Kasai K; Banba N; Hattori Y; Shimoda S
    Life Sci; 1996; 59(14):PL227-34. PubMed ID: 8831807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of GEA 3175 on human platelets; comparison with S-nitroso-N-acetyl-D,L-penicillamine.
    Asplund Persson AK; Palmér L; Gunnarsson P; Grenegård M
    Eur J Pharmacol; 2004 Aug; 496(1-3):1-9. PubMed ID: 15288569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mode of cytostatic action of mesoionic oxatriazole nitric oxide donors in proliferating human hematopoietic cells.
    Vilpo JA; Vilpo LM; Vuorinen P; Moilanen E; Metsä-Ketelä T
    Anticancer Drug Des; 1997 Mar; 12(2):75-89. PubMed ID: 9113063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of glucagon-stimulated glycogenolysis by S-nitroso-N-acetylpenicillamine.
    Brass EP; Vetter WH
    Pharmacol Toxicol; 1993 Jun; 72(6):369-72. PubMed ID: 8395688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low NO concentrations inhibit osteoclast formation in mouse marrow cultures by cGMP-dependent mechanism.
    Holliday LS; Dean AD; Lin RH; Greenwald JE; Gluck SL
    Am J Physiol; 1997 Mar; 272(3 Pt 2):F283-91. PubMed ID: 9087669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts.
    Calderone A; Thaik CM; Takahashi N; Chang DL; Colucci WS
    J Clin Invest; 1998 Feb; 101(4):812-8. PubMed ID: 9466976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of beta- but not alpha 1-mediated adrenergic responses in isolated hearts and cardiomyocytes by nitric oxide and 8-bromo cyclic GMP.
    Ebihara Y; Karmazyn M
    Cardiovasc Res; 1996 Sep; 32(3):622-9. PubMed ID: 8881523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide.
    Jurasz P; Sawicki G; Duszyk M; Sawicka J; Miranda C; Mayers I; Radomski MW
    Cancer Res; 2001 Jan; 61(1):376-82. PubMed ID: 11196190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitric oxide-releasing compounds inhibit the production of interleukin-2, -4 and -10 in activated human lymphocytes.
    Korhonen R; Kosonen O; Hämäläinen M; Moilanen E
    Basic Clin Pharmacol Toxicol; 2008 Oct; 103(4):322-8. PubMed ID: 18684225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacology of analogues of S-nitroso-N-acetyl-DL-penicillamine on human platelets.
    Salas E; Moro MA; Askew S; Hodson HF; Butler AR; Radomski MW; Moncada S
    Br J Pharmacol; 1994 Aug; 112(4):1071-6. PubMed ID: 7524991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.